Does Long Term Psoriasis Data Change The Bull Case For Johnson & Johnson Stock (JNJ)?
Does Long Term Psoriasis Data Change The Bull Case For Johnson & Johnson Stock (JNJ)? Simply Wall Street
Covered in this story
Analyst targets on Johnson & Johnson
- RBC Capital Markets: $255 → $290 by Oct 2027 · Outperform via Investing.com
- Bank of America: $265 → $278 by Sep 2027 · Neutral via AOL.com
- Raymond James: $254 → $280 by Aug 2027 · Outperform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $JNJ yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Johnson & Johnson →Dalsna Finance is currently tracking 44 stories mentioning Johnson & Johnson, the earliest published 11 Jun 2026.
Summary aggregated from Simply Wall Street's public RSS feed. The full reporting belongs to Simply Wall Street — please read it on their site.